Nosocomial Infection Treatment Market Is Expected To Reach USD 36.75 Bn By 2024

Product Summary

The study is given to the analysis of the latest growth trends and prospects for the Nosocomial Infection Treatment market.

The section „Nosocomial Infection Treatment Market“ includes an examination of the situation in major sections of the Nosocomial Infection Treatment market. The markets in European Union countries are examined in more detail, giving a timeline of financial results reported by major 3PL providers in 2017.

Browse full report: https://www.credenceresearch.com/report/nosocomial-infection-treatment-market

Market Insight:

Nosocomial infection, also known as hospital acquired or associated infection (HAI) is defined as an infection developed in patients during the hospital stay that was earlier not present or incubated during admission in the hospital. Nosocomial infection is majorly caused by bacteria, virus, or fungal pathogen and is becoming the leading cause of morbidity and mortality globally, causing enormous economic burden. The nosocomial infection treatment market is anticipated to grow throughout the forecast period. Major factors contributing to the growth of the HAI market is rising prevalence of the nosocomial infection, increasing government initiatives and rising public awareness related to the quality hygiene in hospitals, rising geriatric population immuno-compromised patient, advances in air handling units and other cleaning technologies. Multi-drug resistance is observed in patients mainly due to excessive use of antibiotic which is one of the causes of rising prevalence of nosocomial infection. The regulatory authorities have created set of guidelines for hospitals and clinics and instructed them to abide by these guidelines for prevention of nosocomial infection and adopt best health practices along with a devised strategy to control infections.

The global nosocomial infection treatment market are segmented by infection type as pneumonia, urinary tract infection, blood stream infection, surgical site infection, MRSA, others. Pneumonia, urinary tract infection (UTI), surgical site infection (SSI) and MRSA are the major types of hospital acquired infections that find the highest prevalence.

Nosocomial infection treatment market is segmented on the basis of treatment type as antibacterial, antifungal, antiviral treatment and others. Antibacterial treatment accounted for the largest market share in 2015. As of the current market scenario, North America is the largest regional market for nosocomial infection treatment, followed by Europe and Asia Pacific. North America dominates the global nosocomial infection treatment market attributed to rise in prevalence of nosocomial infections, mounting cases of multi-drug resistant microbial infections and rising demand for advanced therapeutics. Asia Pacific is anticipated to be the fastest growing market during the forecast period. The key factors responsible for its significant growth are emerging economies with developing healthcare market due to pouring investments in healthcare infrastructure by public and private sector, increase in prevalence of nosocomial infection, and high health awareness coupled with growing disposable income.

Market Competition Assessment:

Key players in the nosocomial infection treatment market are

Abbott Vascular Inc., Bayer, Becton, Dickinson and Company, Belimed, BioMerieux, Cantel, Cepheid, Getinge Group, Kimberly-Clark Corp., Merck & Co, Nordion, Pfizer, Roche, Sakura Seiki, BioMérieux, Steris, Johnson & Johnson, Sterigenics International, Inc., Halyard Health, Inc., Advanced Sterilization Products, Matachana Group etc.

Global Nosocomial Infection Treatment Analysis
3.1 Global Nosocomial Infection Treatment Overview
3.2 Epidemiology of Nosocomial Infections
3.3 Guidelines for Nosocomial Infection Control
3.4 Market Dynamics
3.4.1 Market Drivers
3.4.2 Challenges
3.4.3 Opportunities
3.5 Attractive Investment Proposition, 2015
3.6 Market Positioning Analysis of Key Players: Nosocomial Infection Treatment Market, 2015

Chapter 4 Global Nosocomial Infection Treatment Analysis, by Infection Type, 2014-2024 (US$)
4.1 Introduction
4.2 Ventilator Associated Pneumonia
4.3 Urinary Tract Infection
4.4 Blood Stream Infection
4.5 Surgical Site Infection
4.6 Gastrointestinal Infection
4.7 MRSA
4.8 Others (ENT Infections, Skin Infection, and Bone Infection)

Chapter 5 Nosocomial Infection Treatment Analysis, by Treatment Type, 2014-2024 (US$)
5.1 Introduction
5.2 Antibacterial Treatment
5.3 Antiviral Treatment
5.4 Antifungal Treatment
5.5 Others

Chapter 6 Global Nosocomial Infection Treatment, by Geography
6.1 Preface
6.2 North America (U.S. & Canada)
6.3 Europe (U.K., Germany & Rest of Europe)
6.4 Asia Pacific (China, Japan, and Rest of APAC)
6.5 Latin America (Brazil, Mexico and Rest of LATAM)
6.6 Middle East and Africa

Chapter 7 Company Profiles
7.1 Abbott
7.2 Bayer
7.3 Becton, Dickinson and Company
7.4 Belimed
7.5 BioMerieux
7.6 Cantel
7.7 Cepheid
7.8 Getinge Group
7.9 Kimberly-Clark Corp.
7.10 Merck & Co
7.11 Nordion
7.12 Pfizer
7.13 Roche
7.14 Sakura Seiki
7.15 BioMérieux
7.16 Steris
7.17 Johnson & Johnson
7.18 Sterigenics International, Inc.
7.19 Halyard Health, Inc.
7.20 Advanced Sterilization Products
7.21 Matachana Group
7.22 Other Notable Players

“Nosocomial Infection Treatment Market” is a new report by us that explains how companies‘ acquisition expenditures, media spend, business strategies, marketing and sales strategies and practices, and business plan are set to change in 2017-2018. This paper gives you access to the category-level spending forecasts, business challenges, budgets, supplier selection criteria, the current size of the marketing and promotion budgets and investment opportunities for senior-level officials. The report also identifies the expected growth of buyers and suppliers, capital expenditure, staff hiring, M and A, and e-procurement. This report not only gives access to the views and strategies of business decision makers and rivals but also examines their actions circling business priorities. The report also provides access to information categorized by company type and sizes, region,

Introduction and Landscape

Why was the report written?

This report is the result of an extensive survey drawn from Our Research’s elite panel of leading global senior level executives from enterprises such as such as medical devices, mining, packaging, power, oil, and gas, food and beverage, airports and pharmaceutical. The report covers key topics such as appropriation behaviors and strategies, the current size of the marketing and advertising budgets. Besides the report also recognizes the threats and possibilities, economic outlook trends, media channel spending outlooks, M and A expectations, marketing agency selection models, media budgets, business challenges and confidence among senior-level executives across various industries. Most secondary research papers are based on general industry drivers and do not understand the industry officials‘ attitude and changing behaviors, creating a gap in showing the business opportunity of the industry. In an effort to bridge this gap, Our Research created this primary-research based report by selecting the opinions of various stakeholders in the value-chain of the industry

This report offers:

  • Analysis of several products, and regions that would provide the clear understanding of the ongoing and future trends in the global Nosocomial Infection Treatment market
  • Assessment of market dynamics such as drivers, restraints, and opportunities prevalent in the market
  • Quantitative assessment of the current market size and future estimations for the period from 2016 to 2026, along with CAGRs for the period from 2018 to 2026
  • Company profiles that will highlight key information about the imperative players operating in the global Nosocomial Infection Treatment devices market

Here you can get an updated sample on this report: https://www.credenceresearch.com/sample-request/58358

About us:

Credence Research is a worldwide market research and counseling firm that serves driving organizations, governments, non-legislative associations, and not-for-benefits. We offer our customers some assistance with making enduring enhancements to their execution and understand their most imperative objectives. Over almost a century, we’ve manufactured a firm extraordinarily prepared to this task.

Who we are

Credence Research is a worldwide firm, containing more than 15 research consultants and almost 100 research and information professionals.

Our customers mirror our worldwide nature. Around 45% are in Europe, 30% in the Americas, 13% in the Asia Pacific and 12% in the Middle East and Africa.

Our firm is intended to work as one. We are a solitary global research organization united by a solid arrangement of qualities, concentrated on customer effect.

Contact Us:

Credence Research Inc.

105 N 1st ST #429

SAN JOSE

CA 95103

United States

Email:

sales@credenceresearch.com

http://www.credenceresearch.com